Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein–Protein Interaction between Menin and Mixed Lineage Leukemia (MLL)
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Development of potent small molecule inhibitors of protein-protein interactions with optimized druglike properties represents a challenging task in lead optimization process. Here, we report synthesis and structure-based optimization of new thienopyrimidine class of compounds, which block the protein-protein interaction between menin and MLL fusion proteins that plays an important role in acute leukemias with MLL translocations. We performed simultaneous optimization of both activity and druglike properties through systematic exploration of substituents introduced to the indole ring of lead compound 1 (MI-136) to identify compounds suitable for in vivo studies in mice. This work resulted in the identification of compound 27 (MI-538), which showed significantly increased activity, selectivity, polarity, and pharmacokinetic profile over 1 and demonstrated a pronounced effect in a mouse model of MLL leukemia. This study, which reports detailed structure-activity and structure-property relationships for the menin-MLL inhibitors, demonstrates challenges in optimizing inhibitors of protein-protein interactions for potential therapeutic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Krivtsov, A. V., Twomey, D., Feng, Z., Stubbs, M. C., Wang, Y., Faber, J., Levine, J. E., Wang, J., Hahn, W. C., Gilliland, D. G., et al. (2006) · Nature · doi:10.1038/nature04980 · Cited by 1,513 · cited 1×
“2-(2-Cyano-5-((4-((6-(2,2,2-trifluoroethyl)thieno[2,3-d]-pyrimidin-4yl)amino)piperidin-1-yl)methyl)-1H-indol-1-yl)-propanamide (8)—Similar procedure as for 7 but starting with 50 mg (0.”
MethodInhibition of α-helix-mediated protein–protein interactions using designed molecules
Azzarito, V., Long, K., Murphy, N. S., & Wilson, A. J. (2013) · Nature Chemistry · doi:10.1038/nchem.1568 · Cited by 727
Oncogenic protein interfaces: small molecules, big challenges
Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J., & Parker, M. W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3690 · Cited by 312 · cited 1×
“2-(2-Cyano-6-methoxy-4-methyl-5-((4-((6-(2,2,2-trifluoroethyl)thieno[2,3d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1H-indol-1-yl)acetamide (26)— Similar procedure was used as for 7 but starting with 26 mg (0.”
MethodHuman Cancer Protein-Protein Interaction Network: A Structural Perspective
Kar, G., Gursoy, A., & Keskin, O. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000601 · Cited by 235 · cited 1×
“6-Hydroxy-5-((4-((6-(2,2,2-trifluoroethyl)thieno[2,3-d]-pyrimidin-4yl)amino)piperidin-1-yl)methyl)-1H-indole-2-carbonitrile (17)—Similar procedure was used as for 20 but starting with 50 mg (0.”
MethodMorelli, X., Bourgeas, R., & Roche, P. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.05.024 · Cited by 223
Arkin, M. R., & Whitty, A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.05.125 · Cited by 190
Buchwald, P. (2010) · IUBMB Life · doi:10.1002/iub.383 · Cited by 133 · cited 1×
“6-Methoxy-5-((4-((6-(2,2,2-trifluoroethyl)thieno[2,3-d]-pyrimidin-4yl)amino)piperidin-1-yl)methyl)-1H-indole-2-carbonitrile (18)—Similar procedure was used as for 1 but starting with 116 mg (0.”
MethodHe, S., Senter, T. J., Pollock, J., Han, C., Upadhyay, S. K., Purohit, T., Gogliotti, R. D., Lindsley, C. W., Cierpicki, T., Stauffer, S. R., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401868d · Cited by 99 · cited 1×
“4-Chloro-5-((4-((6-(2,2,2-trifluoroethyl)thieno[2,3-d]-pyrimidin-4yl)amino)piperidin-1-yl)methyl)-1H-indole-2-carbonitrile (15)—Similar procedure was used as for 14 but starting with 29 mg (0.”
MethodSelf-citationCierpicki, T., & Grembecka, J. (2015) · Immunological Reviews · doi:10.1111/imr.12244 · Cited by 53
Self-citation
Cited by
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
Meanwell, N. A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01788 · Cited by 2,655
Targeting transcription factors in cancer — from undruggable to reality
Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919
MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
Winters, A. C., & Bernt, K. M. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00004 · Cited by 405
Inhibitors of Protein Methyltransferases and Demethylases
Kaniskan, H. Ü., Martini, M. L., & Jin, J. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00801 · Cited by 297
Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia
Klossowski, S., Miao, H., Kempinska, K., Wu, T., Purohit, T., Kim, E., Linhares, B. M., Chen, D., Jih, G., Perkey, E., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129126 · Cited by 246
“On day 19 after transplantation, mice were split into vehicle and MI-3454 treatment groups of 5 mice per group and treated for 7 consecutive days with vehicle [20% (2-hydroxy-propyl)- β -cyclodextrin, 5% Cremophor] or MI-3454 (120 mg/kg, p.o., b.i.d. and 120 mg/kg, p.o., q.d.).”
Self-citation
Metadata
- Authors
- Borkin, D., Pollock, J., Kempinska, K., Purohit, T., Li, X., Wen, B., Zhao, T., Miao, H., Shukla, S., He, M., Sun, D., Cierpicki, T., & Grembecka, J.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-01-25
- Volume
- 59
- Issue
- 3
- Pages
- 892-913
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2253945020
- Cited by
- 76
- References
- 9
- FWCI
- 8.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein–Protein Interaction between Menin and Mixed Lineage Leukemia (MLL). https://app.cochat.ai/papers/10.1021/acs.jmedchem.5b01305
- The paper
- Borkin, D., Pollock, J., Kempinska, K., Purohit, T., Li, X., Wen, B., Zhao, T., Miao, H., Shukla, S., He, M., Sun, D., Cierpicki, T., & Grembecka, J. (2016). Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein–Protein Interaction between Menin and Mixed Lineage Leukemia (MLL). Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5b01305
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.